Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.
about
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitroEvaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyRationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDSPyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than RitonavirA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceProfile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDSCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Recent key advances in human immunodeficiency virus medicine and implications for ChinaElvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionThe evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Clinical management of HIV drug resistance.Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanismAntiretroviral drugs: critical issues and recent advancesRitonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceBiotransformation of Cobicistat: Metabolic Pathways and EnzymesPharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.Recent advances in antiretroviral drugs.Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?The successes and failures of HIV drug discovery.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.Safety of pharmacoenhancers for HIV therapy.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.Cobicistat : a new opportunity in the treatment of HIV disease?Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Pharmacokinetic enhancers in HIV therapeutics.Darunavir/cobicistat once daily for the treatment of HIV.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Renal effects of novel antiretroviral drugs.
P2860
Q24633870-4012A353-336B-414F-A208-E360A840E4B0Q26750406-DFDCD45D-D38C-4E2D-9D85-0DF040CFCCC7Q26771182-C3B1BF5F-AAC5-4C67-8422-7340A9DEA0D5Q26777251-65E79A7C-C524-4836-B942-B423DE038E44Q27677369-B34B5AEC-C6F6-4C25-8074-E1307C039E32Q27692040-219F1A80-07A6-4BCA-B3D1-B7A67C59472BQ28073206-0179DE41-45F7-4EC0-9936-5826D193CABFQ33680234-D2A866A1-DEA8-4086-B620-6D2D3F921161Q33933502-898D1FAF-3039-42B6-8D48-DA18127F727DQ34634156-70FE1359-3E0E-4EE9-B31F-09ED6C6B7E93Q34976284-A496B4D9-FF81-49EF-99DF-296DB2CF104AQ35023687-7219E5DF-8CA0-4379-BA3C-3BD303D69445Q35261045-52A7F5D1-EB8F-4B89-850D-A0627994B59FQ35933538-D179ECD8-D453-483E-83EF-6E5730936AF7Q36020992-C0A4978A-47DF-4F25-ABD8-A84C74571208Q36072448-19E302C8-79CF-4A81-883B-C973AFA6CA3FQ36541070-18D81EF9-2C83-4586-979A-99C4547CA030Q37207332-052446CD-45AF-496D-9D0A-5D9310453EB8Q37335799-C1678629-73FF-4243-A223-B17D7980AD73Q37696729-4E35B904-98ED-4FBC-AB79-CAFD3A8053C3Q37713076-A55A3501-66B6-4185-AC9C-2EF7ADF26C62Q37779092-E5B269F2-9824-4A44-B7B2-E3F99B6D798EQ37818237-4622F2DE-F83D-4C64-BA09-9CADCBDB755FQ37850890-9DC61395-BA68-45BE-9B1B-A2D9E914E97BQ38009758-4EB13A63-EEDA-4FAC-83F0-AB322A77270BQ38014557-5FF89085-994E-421A-8133-D91E1561C30AQ38030981-9A077E70-24EA-4EC6-BFCD-26A869FFF28AQ38057371-58BACE97-1DAA-4981-AEC4-8548A976A306Q38058501-CF7DA121-7E80-4788-8847-17073A8D48D9Q38087555-D5F9029F-183B-4937-B612-CE54DA997650Q38109095-950B0800-4EA7-4CA6-B490-E45938BA376DQ38171345-DAB19072-D6E1-41C5-A6B4-3F5D1ED3871EQ38171753-D4A60865-FA5E-4CB2-AD02-731C3C9F6E64Q38211165-FA7CBCC5-A279-4F10-BDA7-ED3636E35EDAQ38222092-6C96A462-DB88-41E0-97C5-D5F7433F97F2Q38244014-6A7A98C0-64B9-4C31-B171-60DD213701E8Q38472696-139BB6E5-71DC-4BD5-A636-682FF13D05C1Q38719799-CC88F865-A32B-4933-AF14-4A34DD8052AAQ38836056-78170BA1-29E9-415A-8B89-533EED3E93E3Q38837077-2D505D6E-9156-4796-B67B-EE17D72C4199
P2860
Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@en
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@nl
type
label
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@en
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@en
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.
@en
P2093
A A Mathias
B P Kearney
B P Murray
P2860
P304
P356
10.1038/CLPT.2009.228
P407
P577
2009-12-30T00:00:00Z